15,000 Shares in MaxCyte, Inc. (NASDAQ:MXCT) Bought by AJOVista LLC

AJOVista LLC bought a new position in MaxCyte, Inc. (NASDAQ:MXCT) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 15,000 shares of the company’s stock, valued at approximately $70,000.

Other large investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new position in shares of MaxCyte during the third quarter worth about $31,000. Johnson Investment Counsel Inc. bought a new position in shares of MaxCyte during the 3rd quarter worth approximately $34,000. Aigen Investment Management LP acquired a new stake in shares of MaxCyte in the third quarter valued at approximately $44,000. Nisa Investment Advisors LLC lifted its position in shares of MaxCyte by 47,100.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock worth $55,000 after purchasing an additional 11,775 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in MaxCyte by 350.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $56,000 after purchasing an additional 9,323 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MXCT shares. William Blair restated an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th. BTIG Research lowered their price target on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Finally, Stephens reissued an “overweight” rating and issued a $11.00 price objective on shares of MaxCyte in a report on Tuesday, April 23rd.

MaxCyte Stock Down 1.6 %

Shares of MXCT stock traded down $0.06 during trading on Friday, reaching $3.77. 477,877 shares of the company’s stock were exchanged, compared to its average volume of 451,874. MaxCyte, Inc. has a twelve month low of $2.45 and a twelve month high of $5.55. The firm’s fifty day moving average price is $4.13 and its 200-day moving average price is $4.34.

MaxCyte (NASDAQ:MXCT) last issued its quarterly earnings data on Tuesday, March 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%. The firm had revenue of $15.67 million during the quarter, compared to the consensus estimate of $15.60 million. As a group, research analysts anticipate that MaxCyte, Inc. will post -0.53 EPS for the current year.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.